In Brief: GATT patent extensions

GATT patent extensions: The American public will pay an estimated $6 bil. more for 105 brandname drugs due to patent extensions under the GATT-implementing legislation, according to a report released March 17 and sponsored by the National Association of Pharmaceutical Manufacturers and the National Pharmaceutical Association. The two generic drug associations are funding an economic study being conducted by Stephen Schondelmeyer, PhD, at the PRIME Institute to assess the economic impact of GATT legislation on the American public...